Brain & cognitive performance
Dihexa vs Omberacetam (Noopept)
Noopept has limited human patient studies; Dihexa is preclinical with an FDA human-data gap and a key retracted mechanistic paper. This is an.
At a glance
Dihexa
Omberacetam (Noopept)
Human evidence
FDA states it has not identified human exposure data for drug products containing dihexa acetate by any route.
Human evidence consists mainly of older regional open/comparative studies in patients with vascular or traumatic cognitive impairment; no modern placebo-controlled healthy-adult cognitive-enhancement programme was identified.
Research focus
Experimental cognition, synaptogenesis, neurodegeneration research
Post-stroke cognitive impairment, mild cognitive impairment, neuroprotection; commonly discussed as a nootropic
Regulatory status
Not an approved medicine. FDA lists dihexa acetate among bulk substances with significant safety-information gaps; a UNII/GSRS identity record does not imply approval.
FDA substance records identify omberacetam/Noopept but explicitly note that UNII listing does not imply regulatory review or approval. Regulatory status varies internationally.
Route / formulation
No route has an established human therapeutic safety/dose framework for dihexa itself.
Most clinical literature concerns oral use in neurologic patients; it should not be extrapolated to other formulations or healthy-user 'nootropic' protocols.
No direct head-to-head trial; Dihexa lacks identified human exposure data Noopept has limited human patient studies; Dihexa is preclinical with an FDA human-data gap and a key retracted mechanistic paper. This is an evidence-maturity comparison, not a recommendation.